Eli Lilly And Co vs MGM Resorts International — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while MGM Resorts International trades at $29.27 (market cap $7.55B). The key difference: Eli Lilly And Co is far larger — about 137.7× MGM Resorts International's market cap, and Eli Lilly And Co pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and MGM Resorts International for 91 Days on average.
| LLY | MGM | |
|---|---|---|
Market Cap | $1.04T | $7.55B |
Volume | 3,064,878 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $50.69 |
52-Week Low | $799.57 | $30.00 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $1.09T | $34.85B |
Dividend Yield | 0.59% | 0.03% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement (+0.03%) amid recent volatility following the collapse of Barry Diller's $48.30 per share acquisition proposal. The stock faces bearish technical signals with oversold RSI readings, while fundamentals show mixed results with Q2 2026 earnings beating expectations but net margins declining to 2.4% in 2025. Recent news highlights potential MGM interest in acquiring People Inc., creating uncertainty around strategic direction.
MGM presents a value opportunity with P/S ratio of 0.45 below industry averages, supported by strong analyst consensus ($48.75 price target, 51% buy ratings). However, risks include declining profit margins, failed acquisition attempts, and ongoing debt burden. The stock's current discount to analyst targets suggests potential upside if operational improvements materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →